ABiC, Ab Interno Canaloplasty

ABiC™ is a new, comprehensive MIGS procedure. Performed via a self-sealing, clear corneal incision, ABiC™ conserves the clinically proven benefits of 360-degree viscodilation of Schlemm’s canal provided by traditional Canaloplasty, but with the speed and ease of implementation of an MIGS procedure. Unlike other currently available MIGS procedures, however, ABiC™ preserves tissue and does not require permanent placement of an implant in the eye. It has also been shown to be effective as both a stand-alone procedure and as a combined procedure performed in conjunction with cataract surgery.

  • FDA approved
  • Comprehensive: treats trabecular meshwork, Schlemm’s canal and collector channels
  • No permanent implant or stent
  • Can be performed both with and without cataract surgery
  • 12-month case series results demonstrate an average IOP reduction of 30% and a 50% reduction in medication burden

Removing the Guesswork from MIGS

The most defining aspect of ABiC™ is its comprehensive approach. To date, ABiC™ is the only MIGS procedure that successfully and comprehensively addresses all aspects of potential outflow resistance. Whereas other MIGS procedures treat only one aspect of aqueous outflow, ABiC™ comprehensively accesses, catheterizes, and viscodilates the trabecular meshwork, Schlemm’s canal, and importantly, the distal outflow system, beginning with the collector channels.

The Only MIGS Procedure Performed Outside Cataract Surgery in the USA

Performed via a self-sealing, clear corneal incision, ABiC™ can be combined with cataract surgery in order to optimize time in the operating room, or performed as a stand-alone procedure. To date, ABiC is the only MIGS procedure approved for use outside cataract surgery in the USA. Based on a 228-eye case series by Mark J. Gallardo, MD (El Paso Eye Surgeons, PA) and Mahmoud A. Khaimi, MD (Dean McGee Eye Institute, OK), ABiC achieved a 36.74% reduction in IOP at 12 months (21.5 ± 7.4 mm Hg at baseline to 13.6 ± 1.20 mm Hg).

Physiological Outflow PathwayNon-Physiological Pathway
Collector ChannelsTrabecular MeshworkSchlemm’s CanalSubconjunctival SpaceSupraciliary space
CyPass MicrostentYES
XEN Gel StentYES

iTRACK™ Microcatheter

Featuring a proprietary, patented design, iTrack™ is the only illuminated, micron-scale microcatheter, designed to viscodilate Schlemm’s canal during ABiC (ab-interno canaloplasty). The iTrack™ system comprises the iTrack™ microcatheter, the ViscoInjector™ viscoelastic injector and the iLumin™

Meet the Experts

ABiC: An Evolution of Canaloplasty
Interview with Mahmoud A. Khaimi, MD (USA)

In this video interview, US glaucoma surgeon Dr. Khaimi addresses his experience with Canaloplasty. One of the early adopters of Canaloplasty, he has performed more than 1000 procedures. He is currently pioneering the clinical development of ABiC, an ab-interno MIGS procedure derived from Canaloplasty.

ABiC: Introducing A New MIGS
Interview with Mark J. Gallardo, MD (USA)

According to Mark J. Gallardo, ABiC has worked so well to control his patients’ IOP and to reduce their medication load that it has become his “go-to” procedure for patients requiring (glaucoma) surgical intervention.